Genmab Announces Data to be Presented at the EHA25 Virtual Congress

Media Release


Copenhagen, Denmark, May 14, 2020

Eight industry-sponsored abstracts featuring Genmab programs and partner programs selected for presentation at EHA25 Virtual Congress

Genmab A/S (Nasdaq: GMAB) announced today that eight industry sponsored abstracts regarding Genmab and partner programs were accepted for presentation at the 25^th European Hematology Association (EHA) EHA25 Virtual Congress 2020, taking place virtually on June 11-14, 2020. A list of accepted Industry-sponsored abstracts featured at the congress includes two abstracts on epcoritamab (DuoBody-CD3xCD20), one on HexaBody-CD38, one on DuoHexaBody-CD37 and four daratumumab abstracts. The abstracts have been published on the EHA website and may be accessed via www.ehaweb.org. All e-Poster presentations will be made available on the on-demand Virtual Congress platform Friday, June 12 at 08:30 CEST.

“We are very pleased to see that once again a broad spectrum of data from Genmab’s innovative clinical and pre-clinical proprietary pipeline has been accepted for presentation at the prestigious EHA Congress,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Industry-Sponsored Abstracts are as follows:

Epcoritamab (DuoBody-CD3xCD20):
Subcutaneous epcoritamab (DuoBody-CD3×CD20) induces complete response in heavily pre-treated patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma: Phase 1/2 dose escalation

Evaluation of pharmacodynamic biomarkers of epcoritamab (GEN3013; CD3CD20): Results from a Phase 1/2 dose-escalation study in relapsed/refractory B-cell Non-Hodgkin Lymphoma

HexaBody-CD38:
Superior anti-tumor activity of HexaBody-CD38 in preclinical models of Multiple Myeloma, B Cell Lymphoma and AML

DuoHexaBody-CD37:
DuoHexaBody-CD37 shows potent anti-tumor activity in pre-clinical B-cell lymphoma models in vitro and in vivo

Daratumumab (Submitted by Janssen Biotech, Inc.):
Phase 3 Study of Daratumumab/Bortezomib/Dexamethasone Versus Bortezomib/Dexamethasone in Chinese Patients with Relapsed/Refractory Multiple Myeloma: MMY3009 (LEPUS)

Corticosteriod Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-label, Multicenter, Phase 1b PAVO Study

Impact of Depth of Response and Minimal Residual Disease on Health-Related Quality of Life of Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma